APL-101 (vebreltinib) is an Apollomics Inc. program. Its next catalyst is a Readout in Jan 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Sponsor: Apollomics Inc. (APLM). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for APL-101 (vebreltinib) is a Readout in Jan 2027.
No FDA decision for APL-101 (vebreltinib) is in our archive yet.
Apollomics Inc. (APLM).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.